New Irritable Bowel Syndrome (IBS) Clinical Trial
We are inviting people with IBS to join a clinical study
💡 Help researchers learn more about a new IBS supplement and how it could affect stomach pain and diarrhoea.
💡 Qualify to take part and you could receive study-related care at no cost, as well as compensation.
Click here or scroll down to learn about this study's inclusion criteria ⬇️
📝 Registration Form
If you take part in the research study:
You will receive study-related medical care at no cost
You may gain access to new research treatments, before they are widely available.
No overnight stays!
3 study visits that are out-patient only.
Online assessments including questionnaires and diary throughout the study
You will be financially compensated for your participation in this study.
A gut microbiome report for all participants who complete the study
This unique report will allow you to review personalised, science-based information so you can understand your gut microbiome.
Do your part to help advance breakthroughs in clinical research.
🏥 Study Guide
Who can take part in this study?
In order to be eligible to participate in the study, you must meet all of the following:
- You are aged 18 to 65 years old
- You have IBS
Who is unable to take part in this study?
Unfortunately, if you meet any of the following, this study is not the right fit for you:
- Anyone who currently has, or has a history of inflammatory bowel disease or any other diagnosed disease with abdominal symptoms that can resemble IBS
- Anyone who has used systemic steroids or antibiotics within the past month
How long will the study take?
If you agree to take part, and the study is suitable for you, your participation in the study is expected to last approximately 12 weeks. This includes:
- Completing online questionnaires about your IBS symptoms
- 3 in-person visits to the clinic
- 2 week screening period
- 8 week treatment period
- 2 week follow-up period
What is the purpose of this study?
This study aims to test a potential new treatment for IBS using a Gastrointestinal Reprogramming Product (GaRP) that has been designed by Anatara to address the key underlying factors associated with chronic gastrointestinal conditions like IBS.
GaRP is a dietary supplement composed of multiple microbiomes that has demonstrated safety and tolerability in animal trials.
This is a first in human clinical trial of GaRP, however all individual components of the supplement have previously been studied. The main objective of this trial is to determine the efficacy of two different doses of GaRP in IBS patients during an 8 week treatment period.
What is IBS?
IBS is a common gastrointestinal disorder that is characterised by symptoms such as abdominal pain, bloating, gas, nausea and alternating constipation and diarrhoea. IBS affects about 11% of the global population and as many as 1 in 5 Australians report experiencing symptoms of this disorder in their lifetime.
Where is my nearest study site?
Here is a list of the sites that are currently recruiting for this study:
- ACT, Bruce - Paratus Clinical Research Canberra
- NSW, Blacktown - Paratus Clinical Research Western Sydney
- NSW, Kanwal - Paratus Clinical Research Central Coast
- SA, Adelaide - CSIRO Nutrition and Health Research Clinic
- QLD, Albion - Paratus Clinical Research Brisbane
What if I have other questions about the study?
We are here for you! Click or tap this button to send an email to our Patient Experience team: